Literature DB >> 12102163

Cyclin D3 protein content in human renal cell carcinoma in relation to cyclin D1 and clinico-pathological parameters.

Ylva Hedberg1, Göran Roos, Börje Ljungberg, Göran Landberg.   

Abstract

Aberrations in the G1/S checkpoint are common in malignancies and are probably important for tumor development. Few G1/S studies have been performed on renal cell carcinoma (RCC) and therefore in this study the cyclin D3 protein content in 80 RCCs and that in 12 corresponding normal kidney cortex tissues are characterized using Western blotting. High cyclin D3 protein content was observed in 16% of the tumors and was significantly associated with aneuploidy, high TNM stage, high nuclear grade, high proliferation and young age. There was no association between tumor cyclin D3 and patient survival. The cyclin D3 overexpression was confirmed by immunohistochemical staining of 72 tumors, showing both nuclear and cytoplasmic localization of cyclin D3 in a fraction of the tumors. The cyclin D1 content has earlier been characterized in this tumor material and there was no relation between cyclin D1 and cyclin D3 protein expression. In summary, a fraction of the tumors overexpressed cyclin D3, supporting that various aberrations in the G1/S transition are implicated in RCCs.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12102163     DOI: 10.1080/028418602753669562

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  12 in total

1.  Effects of nuclear-presenting-macrophage colony-stimulating factor on the process of malignancy.

Authors:  Zhen-Yu Cao; Bin Zhang; Qing Rao; Ge Li; Guo-Guang Zheng; Ke-Fu Wu
Journal:  Int J Hematol       Date:  2003-07       Impact factor: 2.490

Review 2.  Cyclin D degradation by E3 ligases in cancer progression and treatment.

Authors:  Shuo Qie; J Alan Diehl
Journal:  Semin Cancer Biol       Date:  2020-01-30       Impact factor: 15.707

3.  Combined effect of cyclin D3 expression and abrogation of cyclin D1 prevent mouse skin tumor development.

Authors:  Xian Wang; Christopher Sistrunk; Paula L Miliani de Marval; Yongbaek Kim; Marcelo L Rodriguez-Puebla
Journal:  Cell Cycle       Date:  2012-01-15       Impact factor: 4.534

4.  TFEB-VEGFA (6p21.1) co-amplified renal cell carcinoma: a distinct entity with potential implications for clinical management.

Authors:  Sounak Gupta; Sarah H Johnson; George Vasmatzis; Binu Porath; Jeannette G Rustin; Priya Rao; Brian A Costello; Bradley C Leibovich; R Houston Thompson; John C Cheville; William R Sukov
Journal:  Mod Pathol       Date:  2017-03-24       Impact factor: 7.842

5.  Immunoreactivity of p27(Kip1), cyclin D3, and Ki67 in conventional renal cell carcinoma.

Authors:  Ambrosi Pertia; David Nikoleishvili; Omar Trsintsadze; Nino Gogokhia; Laurent Managadze; Archil Chkhotua
Journal:  Int Urol Nephrol       Date:  2008-08-05       Impact factor: 2.370

6.  Nucleoporin levels regulate cell cycle progression and phase-specific gene expression.

Authors:  Papia Chakraborty; Yaming Wang; Jen-Hsuan Wei; Jan van Deursen; Hongtao Yu; Liviu Malureanu; Mary Dasso; Douglass J Forbes; David E Levy; Joachim Seemann; Beatriz M A Fontoura
Journal:  Dev Cell       Date:  2008-11       Impact factor: 12.270

7.  Cx31.1 acts as a tumour suppressor in non-small cell lung cancer (NSCLC) cell lines through inhibition of cell proliferation and metastasis.

Authors:  Deqiang Zhang; Chengwen Chen; Yuan Li; Xuping Fu; Yi Xie; Yao Li; Yan Huang
Journal:  J Cell Mol Med       Date:  2012-05       Impact factor: 5.310

8.  The Silencing of CCND2 by Promoter Aberrant Methylation in Renal Cell Cancer and Analysis of the Correlation between CCND2 Methylation Status and Clinical Features.

Authors:  Lu Wang; Yun Cui; Lian Zhang; Jindong Sheng; Yang Yang; Guanyu Kuang; Yu Fan; Qian Zhang; Jie Jin
Journal:  PLoS One       Date:  2016-09-01       Impact factor: 3.240

9.  Expression of cyclin D1, D3, E, and p27 in human renal cell carcinoma analysed by tissue microarray.

Authors:  Y Hedberg; B Ljungberg; G Roos; G Landberg
Journal:  Br J Cancer       Date:  2003-05-06       Impact factor: 7.640

10.  Cell cycle regulation and anticancer drug discovery.

Authors:  Jingwen Bai; Yaochen Li; Guojun Zhang
Journal:  Cancer Biol Med       Date:  2017-11       Impact factor: 4.248

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.